RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma; A multicenter, randomized, phase II trial of the German Anal Cancer Study Group - RADIANCE

Goethe University Frankfurt0 个研究点目标入组 178 人开始时间: 2024年7月15日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 178

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Histologically-confirmed ASCC (both genders) of the anal canal or the anal margin, Leukocytes >3.5 x 10^9/l, Absolute neutrophil count (ANC) 1.5 x 109/l (> 1500 per mm3), Platelet count =100 x 109/l (>100,000 per mm3), Serum bilirubin =1.5 x institutional upper limit of normal (ULN). <>, AST (SGOT), ALT (SGPT), AP = 3x institutional ULN, Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula creatinine clearance, Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of durvalumab. A highly sensitive pregnancy test must be used, Female subjects of childbearing potential must be willing to use a highly effective contraceptive measure as defined in the Clinical Trial Facilitation Group (CTFG) guideline (Recommendations related to contraception and pregnancy testing in clinical trials.). For details see Section 6.1 of the study protocol. Highly effective contraception is required from screening to 90 days after the last dose of durvalumab. (Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.), Male subjects of childbearing potential must agree to use a highly effective method of contraception as outlined in Section 6.1. Contraception, starting from screening to 90 days after the last dose of durvalumab. (Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.), Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up., UICC-Stage IIB-IIIC including T2>4cm Nany (IIB: T3N0M0; IIIA: T1- 2N1M0; IIIB: T4N0M0; IIIC: T3-4N1M0; T2>4cm Nany) according to proctoscopy, pelvic MRI, CT scan of thorax and abdomen, all within 30 days prior to recruitment, For HIV-positive patients: running combined antiretroviral therapy (CART) and undetectable HIV-viral load (HIV Viral load <50 copies/mL and CD4>200/µL)., Age = 18 years, no upper age limit, ECOG-Performance score 0-1, History/physical examination within 30 days prior to recruitment, Written informed consent and any locally-required authorization (e.g. EU Data Privacy Directive in the EU) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, Life expectancy of > 12 months, Body weight >30kg, Hemoglobin =9.0 g/dl

排除标准

•UICC-Stage I-IIA ASCC defined as cT1N0M0 or cT2 <4cm N0M0 disease, Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria: -Patients with Grade =2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Chairman. -Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Chairman, Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment, other than the study medication. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable, Previous radiotherapy treatment to the pelvis or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug, Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab., History of allogenic organ transplantation., Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: -Patients with vitiligo or alopecia -Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement -Any chronic skin condition that does not require systemic therapy -Patients without active disease in the last 5 years may be included but only after consultation with the study chairman -Patients with celiac disease controlled by diet alone, Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent, History of leptomeningeal carcinomatosis or any other metastatic disease, History of active primary immunodeficiency, Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA., Second malignancy other than basalioma or cervical/genital/ neoplasia in situ, Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst receiving durvalumab and up to 30 days after the last dose of durvalumab., Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients., Female

研究者

发起方

Goethe University Frankfurt

相似试验

已完成

2 期

Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma. A multicenter, randomized, phase II trial of the German Anal Cancer Study GroupC21Malignant neoplasm of anus and anal canal

DRKS00020739Goethe Universität; Universitätsklinikum Frankfurt Goethe-Universität180

招募中

1 期

Radiochemotherapy +/- Durvalumab for locally-advanced Anal CarcinomaA multicenter, randomized, phase II trial of the German Anal Cancer Study Groupanal cancer (UICC-Stage IIB-IIIC, incl. T2>4cm Nany )MedDRA version: 21.1Level: PTClassification code 10002136Term: Anal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10002137Term: Anal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-003005-25-ATniversity Hospital Frankfurt, Goethe University178

进行中（未招募）

1 期

EUCTR2018-003005-25-DEniversity Hospital Frankfurt, Goethe University178

进行中（未招募）

1 期

Study of advacned resectable head and neck cancer with immunotherapy and radiotherapy before surgeryAdvanced resectable head and neck tumorMedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-001641-40-ITISTITUTI FISIOTERAPICI OSPITALIERI14

进行中（未招募）

1 期

Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

EUCTR2019-002537-11-FIOslo University Hospital100